Breast cancer accounts for 25% of all types of cancer in women, and triple negative breast
cancer (TNBC) comprises around 15~ 20% of breast cancers. Conventional chemotherapy …

Immunotherapies such as immune checkpoint blockade and adoptive cell transfer have
revolutionized cancer treatment, but further progress is hindered by our limited …

Background and aims Tumour‐infiltrating lymphocytes (TIL s) in breast cancer (BC) provide
prognostic and predictive information. The aim of this study was to assess the spatial and …

Around 77 new oncology drugs were approved by the FDA in the past five years; however,
most cancers remain untreated. Small molecules and antibodies are dominant therapeutic …

Cancer is the second leading cause of death globally and its incidence and mortality are
rapidly increasing worldwide. The dynamic interaction of immune cells and tumor cells …

Objective Triple-negative breast cancer (TNBC) presents a clinical challenge as an
aggressive tumor, correlated with unfavorable prognosis. Tumor-infiltrating lymphocytes …

Triple negative breast cancers (TNBCs) are molecularly heterogeneous, and the link
between their aggressiveness with African ancestry is not established. We investigated …

Background Breast cancer is the most common cancer and the leading cause of death
among women. KRAS is known as an oncogene, its expression also associates with cancer …

Tumours with a high mutation burden exhibit considerable neoantigens and tumour-
infiltrating lymphocytes. RNA editing by ADAR1 is a source of changes in epitope. However …

Metastatic triple-negative breast cancer (mTNBC) has the worst prognosis among breast
cancer subtypes. Immune checkpoint inhibitors (ICIs) plus chemotherapy have promising …